These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 37787999)

  • 81. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
    Kanwal R; Shukla S; Walker E; Gupta S
    Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
    Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW
    BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440
    [TBL] [Abstract][Full Text] [Related]  

  • 84. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.
    Swaminathan SK; Roger E; Toti U; Niu L; Ohlfest JR; Panyam J
    J Control Release; 2013 Nov; 171(3):280-7. PubMed ID: 23871962
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A Validation Study of CD133 as a Reliable Marker for Identification of Colorectal Cancer Stem-Like Cells.
    You CZ; Xu H; Zhao FS; Dou J
    Bull Exp Biol Med; 2024 Jan; 176(3):369-375. PubMed ID: 38340198
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
    Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
    J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
    [TBL] [Abstract][Full Text] [Related]  

  • 87. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
    Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
    Martín-Otal C; Lasarte-Cia A; Serrano D; Casares N; Conde E; Navarro F; Sánchez-Moreno I; Gorraiz M; Sarrión P; Calvo A; De Andrea CE; Echeveste J; Vilas A; Rodriguez-Madoz JR; San Miguel J; Prosper F; Hervas-Stubbs S; Lasarte JJ; Lozano T
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35918123
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
    Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Redirection of CAR-T Cell Cytotoxicity Using Metabolic Glycan Labeling with Unnatural Sugars.
    Cha JH; Kim E; Lee HJ; Lee YH; Lee J; Kim E; Kim CH
    J Med Chem; 2023 Jun; 66(12):7804-7812. PubMed ID: 37261887
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
    Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion.
    Luo H; Su J; Sun R; Sun Y; Wang Y; Dong Y; Shi B; Jiang H; Li Z
    Clin Cancer Res; 2020 Oct; 26(20):5494-5505. PubMed ID: 32816947
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
    Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
    Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Spatiotemporal dynamics of tumor - CAR T-cell interaction following local administration in solid cancers.
    Owens K; Rahman A; Bozic I
    bioRxiv; 2024 Aug; ():. PubMed ID: 39257746
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer.
    Erler P; Kurcon T; Cho H; Skinner J; Dixon C; Grudman S; Rozlan S; Dessez E; Mumford B; Jo S; Boyne A; Juillerat A; Duchateau P; Poirot L; Aranda-Orgilles B
    Sci Adv; 2024 Aug; 10(35):eadn9857. PubMed ID: 39213364
    [TBL] [Abstract][Full Text] [Related]  

  • 97. CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects.
    Ercilla-Rodríguez P; Sánchez-Díez M; Alegría-Aravena N; Quiroz-Troncoso J; Gavira-O'Neill CE; González-Martos R; Ramírez-Castillejo C
    Front Immunol; 2024; 15():1333150. PubMed ID: 39091493
    [TBL] [Abstract][Full Text] [Related]  

  • 98. New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat.
    Sloan AR; Thapliyal M; Lathia JD
    Clin Cancer Res; 2024 Feb; 30(3):477-479. PubMed ID: 38038689
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases.
    Kieliszek AM; Mobilio D; Upreti D; Bloemberg D; Escudero L; Kwiecien JM; Alizada Z; Zhai K; Ang P; Chafe SC; Vora P; Venugopal C; Singh SK
    Clin Cancer Res; 2024 Feb; 30(3):554-563. PubMed ID: 37787999
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy.
    Han Y; Sun B; Cai H; Xuan Y
    Cancer Immunol Immunother; 2021 Oct; 70(10):2795-2803. PubMed ID: 33635343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.